5-ó2-(三氟甲氧基)苯基-2-糠醛 | 306936-00-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-ó2-(三氟甲氧基)苯基-2-糠醛
• 中文别名: 5-[2-(三氟甲氧基)苯基]糠醛；5-[2-(三氟甲氧基)苯基]-2-呋喃甲醛；5-[2-(三氟甲氧基)苯基]-呋喃-2-甲醛
• 英文名称: 5-[2-(trifluoromethoxy)phenyl]-2-furaldehyde
• 英文别名: 5-[2-(trifluoromethoxy)phenyl]furan-2-carbaldehyde
• CAS: 306936-00-5
• 化学式: C₁₂H₇F₃O₃
• mdl: MFCD00278715
• 分子量: 256.181
• InChiKey: UTGWIIGCXFJJHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  71-73°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090

SDS

Name:	5-[2-(Trifluoromethoxy)phenyl]-2-furaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	306936-00-5

Section 1 - Chemical Product MSDS Name:5-[2-(Trifluoromethoxy)phenyl]-2-furaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306936-00-5	5-[2-(Trifluoromethoxy)phenyl]-2-fural	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Air sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306936-00-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 71 - 73 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H7F3O3
Molecular Weight: 256

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to air.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306936-00-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-[2-(Trifluoromethoxy)phenyl]-2-furaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 306936-00-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306936-00-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306936-00-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-ó2-(三氟甲氧基)苯基-2-糠醛 在 氨 、 氢气 作用下， 以 叔丁醇 为溶剂， 反应 15.0h， 以76%的产率得到[5-[2-(Trifluoromethoxy)phenyl]furan-2-yl]methanamine
  参考文献：
  名称：

  MOF 衍生的钴纳米粒子催化胺的一般合成

  摘要：

  MOF 为制造胺奠定了基础 还原胺化是化学家用来制造碳氮键的常用方法。该反应通常需要贵金属催化剂，将氨或其他胺与羰基化合物偶联，然后与氢气偶联。贾加迪什等人。报告了一类非贵重的钴纳米粒子，可在非常广泛的底物上催化这种反应，包括具有药用价值的复杂分子（参见 Chen 和 Xu 的观点）。钴首先嵌入金属有机框架 (MOF) 中，加热后转变为石墨壳。催化剂可以方便地从产品中分离出来，最多可循环使用六次。科学，这个问题 p。326; 另见第。304 由金属-有机骨架前体制备的钴纳米颗粒可催化非常广泛的还原胺化反应。用于合成药物相关化合物的贱金属催化剂的开发仍然是化学研究的一个重要目标。在这里，我们报告说，由石墨壳包裹的钴纳米颗粒是广泛有效的还原胺化催化剂。它们方便实用的制备需要在碳上模板组装钴-二胺-二羧酸金属有机骨架，然后在惰性气氛下热解。所得稳定且可重复使用的催化剂对于合成伯胺、仲胺、叔胺和 N-甲胺（超过

  DOI：

  10.1126/science.aan6245
• 作为产物：
  描述：

  5-溴-2-呋喃甲醛 、 2-(三氟甲氧基)苯硼酸 在 palladium diacetate 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 16.0h， 生成 5-ó2-(三氟甲氧基)苯基-2-糠醛
  参考文献：
  名称：

  Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid

  摘要：

  A novel series of nonnucleoside HCV NS5B polymerase inhibitors were prepared from (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid, a high throughput screening lead. SAR studies combined with structure based drug design focusing on the southern heterobiaryl region of the template led to the synthesis of several potent and orally bioavailable lead compounds. X-ray crystallography studies were also performed to understand the interaction of these inhibitors with HCV NS5B polymerase.

  DOI：

  10.1016/j.bmcl.2005.03.066

文献信息

• Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries
  作者：Tobias J. Hauke、Thomas Wein、Georg Höfner、Klaus T. Wanner

  DOI：10.1021/acs.jmedchem.8b01602

  日期：2018.11.21

  study describes the screening of dynamic combinatorial libraries based on nipecotic acid as core structure with substituents attached to the 5- instead of the common 1-position for the search of novel inhibitors of the GABA transporter GAT1. The generated pseudostatic hydrazone libraries included a total of nearly 900 compounds and were screened for their binding affinities toward GAT1 in competitive mass

  这项研究描述了筛选以菊苣酸为核心结构的动态组合文库的筛选方法，该结构具有取代基附着在5位而不是常见的1位上，以寻找GABA转运蛋白GAT1的新型抑制剂。生成的伪静态文库总共包含近900种化合物，并在基于竞争质谱（MS）的结合试验中筛选了它们对GAT1的结合亲和力。最高亲和力的腙表征（与顺-构型外消旋- 16gf结合和吸收实验中带有一个5-（1-萘基）呋喃-2-基残基和一个最有效的四原子间隔基）揭示了GAT1的变构相互作用，迄今为止尚无关于其他任何尼克酸衍生物的报道。因此，本文引入的5-取代的庚酸衍生物可以用作研究由GAT1介导的变构调节的GABA转运的有价值的工具，并且还可以作为新一类GAT1抑制剂的起点。
• Tetrahydroquinoline derivatives as antithrombotic agents
  申请人：——

  公开号：US20030225110A1

  公开（公告）日：2003-12-04

  This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa; pharmaceutical compositions containing the same; and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.

  这项发明通常涉及四环四氢喹啉化合物及其类似物，以及其药用盐形式，这些化合物是选择性抑制丝氨酸蛋白酶酶，特别是VIIa因子的；含有同样化合物的药物组合物；以及将其用作抗凝剂调节凝血级联的方法。
• [EN] IMIDAZOLE-BASED ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS À BASE D'IMIDAZOLE
  申请人：PROCOMCURE BIOTECH GMBH

  公开号：WO2016087618A1

  公开（公告）日：2016-06-09

  The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.

  本发明涉及新型治疗剂，适用于治疗哺乳动物疾病，特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含上述剂的药物组合物在治疗哺乳动物的医疗状况中的使用，特别是在治疗微生物感染中的使用。本发明的剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊意义。
• Generation and Screening of Oxime Libraries Addressing the Neuronal GABA Transporter GAT1
  作者：Felix T. Kern、Klaus T. Wanner

  DOI：10.1002/cmdc.201402376

  日期：2015.2

  present study was to transfer the concept of library screening by MS binding assays, so far applied to pseudostatic hydrazine libraries, to static oxime libraries to screen for new potent inhibitors of mGAT1, the most abundant GABA transporter in the central nervous system that represents a validated drug target for the treatment of epilepsy. Library generation was performed by reaction of guvacine derivatives

  本研究的目的是将到目前为止已应用于假静态肼文库的MS结合测定法转移文库筛选的概念，转移至静态肟文库中以筛选新型强效抑制剂mGAT1，mGAT1是中枢神经系统中最丰富的GABA转运蛋白。代表治疗癫痫病的有效药物靶标。文库的产生是通过将具有羟胺官能度的番石榴碱衍生物与各种四种醛进行反应来进行的。稀释后，通过竞争性MS结合测定法筛选文库。解卷积实验可以识别最活跃的文库中的命中，然后将它们重新合成以进行生物学评估。这样，鉴定出一系列显示结合亲和力≥8.00（p Ki）在mGAT1，在功能性GABA吸收试验中，其中一种是迄今为止已知最有效的mGAT1抑制剂，pIC 50值为8.27±0.03。
• [EN] NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES À BASE D'IMIDAZOLE
  申请人：PROCOMCURE BIOTECH GMBH

  公开号：WO2016087615A1

  公开（公告）日：2016-06-09

  The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.

  本发明涉及一种新型化合物，其化学式为(I)，适用于作为治疗剂用于治疗哺乳动物疾病，特别是适用于治疗哺乳动物微生物感染的新型治疗剂。本发明还涉及包含所述治疗剂的药物组合物在治疗哺乳动物的医疗状况中的使用，特别是在治疗微生物感染方面的使用。本发明的治疗剂和药物组合物在治疗与抗生素耐药微生物相关的疾病方面具有特殊的相关性。本发明还涉及制备所述治疗剂的方法。